A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment

Song, Haoming; Sun, Xiaochuan; Zhang, Liang; Zhao, Lin; Guo, Zhen; Fan, Huiying; Zhong, Aihua; Niu, Wei; Dai, Yunhua; Zhang, Liyi; Shi, Zheng; Li, Xiaoping; Lu, Jim

doi:10.1016/j.jpsychires.2014.03.008

Cited by 76 publications

(53 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numata [28] et al showed that significant diagnostic differences in DNA methylation were observed at 363 CpG sites in the discovery set for MDD patients, and maternal depression was associated with DNA methylation alterations in maternal T lymphocytes, neonatal cord blood T lymphocytes, and adult offspring hippocampi [29]. In addition, miRNAs (miR-16 [30,31], miR-221-3p, miR-34a-5p, let-7d-3p, and miR-451a [32], miRNA-26b, miRNA-1972, miRNA-4743, miRNA-4498, and miRNA-4485 [16]) were found to involve the development of MDD, and the changes of miRNA expression were correlated with the improvement of symptoms [33–35]. These findings suggest research attention to should include another non-coding RNA, lncRNA.…”

Section: Discussionmentioning

confidence: 99%

Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder

Cui

Sun²,

Niu

et al. 2016

Med Sci Monit

Self Cite

View full text Add to dashboard Cite

BackgroundThe criteria for diagnosing depression are based on behavioral observation and self-reporting of symptoms by the patients or guardians without any biological validation of the disease. This study aimed to identify long non-coding RNAs (lncRNAs) in peripheral blood mononuclear cells (PBMCs) as robust and predictive biomarkers for diagnosis and therapy response in major depressive disorder (MDD).Material/MethodsWe used human lncRNA 3.0 microarray profiling (which covers 30,586 human lncRNAs), using PBMCs from five MDD patients and five controls. Differentially expressed lncRNAs in the PBMCs of MDD patients were identified, of which 10 candidate lncRNAs were selected for real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis in a larger cohort of 138 MDD patients and 63 healthy controls. Then among the 138 MDD patients who received standard antidepressant treatment, 30 were randomly selected for lncRNAs expression retesting and symptomatology assessments after three-weeks and six-weeks of antidepressant treatment.ResultsSix lncRNAs (TCONS_00019174, ENST00000566208, NONHSAG045500, ENST00000517573, NONHSAT034045, and NONHSAT142707) were significantly downregulated in MDD patients compared to control patients, and the area under the receiver operator curve (ROC) of these six lncRNAs cases, combined, was 0.719 (95% confidence interval (CI): 0.617–0.821). There was no difference in the expression of these six lncRNAs based on gender (p>0.05) or age (p>0.05).ConclusionsThese results suggest that the combined expression of six lncRNAs in PBMCs may serve as a potential biomarker for diagnosis and therapy response of MDD in the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder

Cui

Sun²,

Niu

et al. 2016

Med Sci Monit

Self Cite

View full text Add to dashboard Cite

show abstract

“…A subsequent study using postmortem brains from the dorsolateral frontal cortex (35 SCZ cases vs 34 controls) uncovered reduced expression of both GRID1 (a target of miR-181b) and miR-346, hosted in intron-2 of GRID1, in SCZ [148]. Based on more recent studies of blood cells, while the expression of miR-181b as well as miRNA-7, miRNA-30e and miRNA-34a were increased in SCZ patients, the expression of miR-181b was downregulated by antipsychotic drugs, predicting an improvement in the negative symptoms [149].…”

Section: Refmentioning

confidence: 99%

An Update on the Epigenetics of Psychotic Diseases and Autism

2015

View full text Add to dashboard Cite

The examination of potential roles of epigenetic alterations in the pathogenesis of psychotic diseases have become an essential alternative in recent years as genetic studies alone are yet to uncover major gene(s) for psychosis. Here, we describe the current state of knowledge from the gene-specific and genome-wide studies of postmortem brain and blood cells indicating that aberrant DNA methylation, histone modifications and dysregulation of micro-RNAs are linked to the pathogenesis of mental diseases. There is also strong evidence supporting that all classes of psychiatric drugs modulate diverse features of the epigenome. While comprehensive environmental and genetic/epigenetic studies are uncovering the origins, and the key genes/pathways affected in psychotic diseases, characterizing the epigenetic effects of psychiatric drugs may help to design novel therapies in psychiatry.

show abstract

“…Likewise, levels of hsamiR-30e and hsa-miR-181b were altered in opposite directions [124126] in studies using plasma from people with Sz. It has been reported that antipsychotic treatment is associated with changes of miRNA levels in human plasma [124,128] and Tlymphocyte cell lines [114] . The expression levels of hsa-miR-365, hsa-miR-520c-3p, and hsa-miR-181b in plasma were significantly downregulated after antipsychotic treatment [124,128] , of these, miRNA-181b expression levels were positively correlated with the improvement of negative symptoms [124] .…”

Section: Epigenetics and Micrornamentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

135

108

View full text Add to dashboard Cite

Identifying biomarkers that can be used as diagnostics or predictors of treatment response (theranostics) in people with schizophrenia (Sz) will be an important step towards being able to provide personalized treatment. Findings from the studies in brain tissue have not yet been translated into biomarkers that are practical in clinical use because brain biopsies are not acceptable and neuroimaging techniques are expensive and the results are inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for Sz as a valid alternative. Although there are some encouraging preliminary data to support the notion of peripheral biomarkers for Sz, it must be acknowledged that Sz is a complex and heterogeneous disorder which needs to be further dissected into subtype using biological based and clinical markers. The scope of this review is to critically examine published blood-based biomarker of Sz, focusing on possible uses for diagnosis, treatment response, or their relationship with schizophreniaassociated phenotype. We sorted the studies into six categories which include: (1) brain-derived neurotrophic factor; (2) inflammation and immune function; (3) neurochemistry; (4) oxidative stress response and metabolism; (5) epigenetics and microRNA; and (6) transcriptome and proteome studies. This review also summarized the molecules which have been conclusively reported as potential blood-based biomarkers for Sz in different blood cell types. Finally, we further discusses the pitfall of current blood-based studies and suggest that a prediction model-based, Sz specific, blood World Journal of Psychiatry W J P oriented study design as well as standardize blood collection conditions would be useful for Sz biomarker development.

show abstract

A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment

Cited by 76 publications

References 47 publications

Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder

Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder

An Update on the Epigenetics of Psychotic Diseases and Autism

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Contact Info

Product

Resources

About